Last reviewed · How we verify
NCT05241496
Lidocaine Spray 10% Versus Oral Ibuprofen Tablets in Pain Control During Copper Intrauterine Device Insertion
NA trial testing The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration in Lidocaine Toxicity in 1 participant. Status unknown.
14 December 2022
Quick facts
| Lead sponsor | Marina Ramsis Aziz Ghaly |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 15 December 2021 |
| Primary completion | 14 December 2022 |
| Estimated completion | 10 October 2023 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration
Conditions studied
- Lidocaine Toxicity — all drugs for Lidocaine Toxicity →
Sponsor
Marina Ramsis Aziz Ghaly
Who can join
Eligibility, female only, with Lidocaine Toxicity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The intrauterine contraceptive device (IUD) is the most commonly used form of reversible contraception worldwide; the predominant type of product, the copper IUD (a plastic T-shaped device with copper affixed to it) was developed over 30 years ago and has become the standard bearer for intrauterine contraception, due to its long-term effectiveness, safety and affordability . Inconsistent use and discontinuation of contraceptives are major causes of unintended pregnancy . The failure rate of the patch or ring is 20 times higher than that of long acting reversible contraceptives (LARCs) . Increasing acceptability and use of LARC methods like the intrauterine device (IUD) is an important strategy to reduce the risk of unintended pregnancy
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05241496
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05241496 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Marina Ramsis Aziz Ghaly
- Last refreshed: 19 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05241496.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing